AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Inc. is trading at $11.24, down 2.09% on the session. The 50 day average sits at $7.87 and the 200 day at $4.95, which puts the stock in a uptrend. RSI is at 62, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $10.44 with resistance near $12.15, so that band frames the current range. Average daily movement is roughly $0.86, or about 7.6% of the share price, which is what any stop placement has to allow for. The overall health score of 78 out of 100 combines a trend score of 100, momentum of 88 and a risk score of 28.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.